Ask about this productRelated genes to: AKR1C2 Blocking Peptide
- Gene:
- AKR1C2 NIH gene
- Name:
- aldo-keto reductase family 1 member C2
- Previous symbol:
- DDH2, TDD
- Synonyms:
- DD, BABP, DD2, HAKRD, MCDR2
- Chromosome:
- 10p15.1
- Locus Type:
- gene with protein product
- Date approved:
- 1994-09-14
- Date modifiied:
- 2016-10-05
Related products to: AKR1C2 Blocking Peptide
Related articles to: AKR1C2 Blocking Peptide
- The clinical utility of integrated proteogenomic biomarkers for predicting chemotherapy response in triple-negative breast cancer remains underexplored. We prospectively analyzed paired baseline and post-treatment tumor samples from 50 patients with stage II-III TNBC treated with anthracycline- and taxane-based neoadjuvant chemotherapy, integrating whole-exome sequencing, RNA sequencing, global proteomics, and phosphoproteomics. - Source: PubMed
Publication date: 2026/04/14
Lee Dong KiKim Min HwanHwang YumiKim Seul-GiRyu Won-JiKim Geon-UkYun Hyun MyoungPark ShinyoungLee Jeong DongHan Hyun JuKim Gun MinKim Kyung-HeePark Jong BaeKim Min JungKoo Ja SeungKim Jee YePark Hyung SeokKim Seung IlGee Heon YungPark SehoSohn Joohyuk - There is a need for novel therapies for diabetic retinopathy (DR) because existing therapies treat only certain features of DR and do not work optimally for all patients. While proteomic studies provide insight into disease pathobiology, they are often limited to small sample sizes due to high costs, limiting their generalizability and reproducibility. Moreover, they often yield lists of tens to hundreds of proteins with differential expression, making it difficult to prioritize the most biologically relevant biomarkers beyond using arbitrary fold-change and false-detection rate cutoffs. Here, we applied a two-stage multimodal AI approach: first, we integrated EHR and proteomics data to rationally prioritize candidate protein biomarkers and, next, validated these biomarkers in an independent cohort. These protein biomarkers of DR are rooted in the EHR data and thereby more likely to be biological drivers of disease. - Source: PubMed
Publication date: 2026/02/24
Lin Jonathan BMataraso Samson JChadha MadhumeetaVelez GabrielMruthyunjaya PrithviAghaeepour NimaMahajan Vinit B - Primary intracerebral hemorrhage (ICH) is a severe stroke subtype characterized by high mortality and disability rates, largely attributable to secondary brain injury (SBI). While programmed cell death (PCD) pathways contribute to SBI, their mechanisms remain incompletely understood. This research investigated PANoptosis, a newly defined integrated PCD pathway, and its interactions with immune responses in ICH. - Source: PubMed
Publication date: 2026/03/06
Chen ZhaohuiZhang XueyuanDeng ZhichengLuo JialiHan ChunyangWeng Yinlun - This study aimed to investigate the association of the AKR1C2-I4-sv245 polymorphism in the aldo-keto reductase family 1 member C2 (AKR1C2) gene with litter size in Xiang pigs. Polymorphism analysis demonstrated that the "ID" genotype was dominant in Xiang pigs, while "D" was the dominant allele. The DD genotype was most common in high-fertility Xiang pigs (XL), while the ID genotype was predominant in low-fertility Xiang pigs (XS). The association analysis results indicated that the litter size of the XL group in Xiang pigs was significantly higher than that of the XS group across all parity levels (P < 0.05). A significant association was observed between the AKR1C2-I4-sv245 polymorphism and the litter size in Xiang sows (P < 0.01), with the DD genotype exhibiting a higher litter size than the ID and II genotypes. Bioinformatics analysis revealed that the deleted segment contained a short interspersed element (SINE), three exon splicing enhancers, four intron splicing enhancers, and other regulatory elements associated with gene expression. Transfection of HEK-293T cells with the EGFP reporter gene confirmed the inhibitory effect of the SINE on transcription, demonstrating that its insertion significantly repressed reporter gene expression. Relative expression analysis showed that AKR1C2 mRNA and protein levels were higher in the DD genotype compared to the II genotype and in the ID genotype compared to the II genotype. Collectively, these results substantiated the regulatory role of SINE in gene expression and highlighted the potential of AKR1C2-I4-sv245 as a promising DNA marker for improving litter size in Xiang pigs. - Source: PubMed
Publication date: 2026/02/28
Wang LanChen XiaGuo MingchuanQi FenfangLi JianLiu YaxueNiu XiWang QiangRan XueqinWang Jiafu - The aldo-keto reductase isoenzymes AKR1C1-3 regulate local steroid hormone availability through the interconversion of active and inactive ligands, thereby modulating prereceptor signaling. This regulatory mechanism has been implicated in the progression of hormone-dependent malignancies, highlighting AKR1C enzymes as attractive therapeutic targets for endocrine-related cancers. The AKR1C family is also known to mediate resistance to multiple classes of chemotherapeutic agents through various mechanisms. Inhibition of AKR1C enzymes may therefore potentiate the cytotoxic effects of chemotherapeutic agents. Building on our recent work describing potent A-ring halogenated 13α-estrone-based AKR1C inhibitors, we now report further structural modifications directed C-H activation on the same scaffold. Following the introduction of a directing group, hydroxylation or acetoxylation was performed at the C-2 position. The newly synthesized compounds were evaluated against recombinant AKR1C1-3 enzymes. Notably, two new derivatives (4 and 6a) exhibited low micromolar, isoform-selective inhibitory activity against AKR1C2. Moreover, using molecular docking, we postulated the binding conformations of active pyridyloxy derivative (6a), triazinyl derivative (7) and aryl carbamate (4) within the AKR1C2 binding site, with all of them showing key interactions with Trp86, Val128, Ile129 and Trp227. The AKR1C2 inhibitors identified in this study represent promising starting points for the development of novel therapeutic agents, limiting metastatic dissemination, particularly in certain aggressive tumor types. Given that AKR1C1-3 isoenzymes often catalyze overlapping biochemical transformations, inhibition of one member may be compensated by another. Thus, while selective AKR1C inhibitors remain valuable, the development of pan-inhibitors also represents a promising therapeutic strategy. - Source: PubMed
Publication date: 2026/02/27
Mernyák ErzsébetGjorgoška MarijaSinreih MasaKotnik AljažZanoškar ZalaGodec AjdaJukič MarkoBren UrbanIgnácz RebekaSzőri KornélKele ZoltánHunyadi AttilaRižner Tea Lanišnik